Amryt Pharma's Q4 FY21 Sales, FY22 Guidance Shy Of Street Consensus

  • Amryt Pharma Plc's AMYT Q4 FY21 sales increased 29% Y/Y to $54.8 million, missing the consensus of $56.81 million.
  • The growth was driven by metreleptin revenues that increased 44% to $31.9 million.
  • Cash of $113 million at December 31, 2021 (2020: $118.8M)
  • The Company reported a wider operating loss of $(50.5) million compared to $(13.9) million a year ago.
  • Amryt posted Q4 EPS of $0.07, a shift from an EPS loss of $(0.28), compared to the consensus of $(0.15).
  • Last month, the FDA asked Amryt to submit additional confirmatory evidence of effectiveness for Oleogel-S10 in Epidermolysis Bullosa.
  • During Q2 2022, Amryt intends to discuss the nature of the data required to address the FDA concerns.
  • The EMA review process for Oleogel-S10 in EB is ongoing, and Amryt has responded to outstanding questions. 
  • The EMA has proposed an Ad-Hoc Expert Group to provide external and independent EB-specific advice. The Ad-Hoc Expert Group is scheduled to meet on March 15, 2022.
  • Guidance: Amryt Pharma expects FY 2022 revenue of $260 million - $270 million, up 17% - 21%, lower than the consensus of $341.17 million.
  • Price Action: AMYT shares are up 7.21% at $6.99 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechEarningsNewsGuidanceHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!